Ana Cordero Guijarro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ana Cordero Guijarro has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Alba Naya Prieto
Pulmonology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; Intermediate Respiratory Care Unit, Instituto de Investigaciones Sanitarias (IIS).Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Réseau Européen de Ventilation Artificielle (REVA), Madrid, Spain
1 shared publication - Alfonso Cabello
Division of Infectious Diseases, Fundación Jiménez Díaz University Hospital, Research Health Institute, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
1 shared publication - Alicia Macías Valcayo
IIS-Fundación Jiménez Díaz, UAM
1 shared publication - Antonio Broncano-Lavado
Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Av. Reyes Católicos, 2, 28040 Madrid, Spain
1 shared publication - Aws Waleed Mohammed Al-Hayani
Hospital Universitario Fundación Jiménez Díaz Madrid Spain
1 shared publication Beatriz Álvarez Álvarez
Hospital Universitario Fundacion Jimenez Diaz - Universidad Autonoma de Madrid
1 shared publication
Latest Publications
- Open Access
Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late
Summary: Introduction: Tocilizumab is an interleukin 6 receptor antagonist which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), aiming to ameliorate the cytokine release syndrome (CRS) -induced acute respiratory distress syndrome (ARDS). However, there is no data about the best moment for its administration along the course of the disease. Methods: We provided tocilizumab on a compassionate-use basis to patients with SSP hospitalized (excluding intensive care and intubated cases) who required oxygen support to have a saturation >93%. Primary endpoint was intubation or death after 24 hours of its administration. Patients received at least one dose of 400 mg intravenous tocilizumab during March 8-2020, through April 20-2020. Findings: A total of 207 patients were studied and 186 analysed. The mean age was 65 years and 68% were male. A co-existing condition was present in 68 % of cases. At baseline, 114 (61%) required oxygen support with FiO2 >0.5 % and 72 (39%) ≤0.5%. Early administration of tocilizumab, when the need of oxygen support was still below FiO2 ≤0.5%, was significantly more effective than given it in advanced stages (FiO2 >0.5 %), achieving lower rates of intubation or death (13% vs 37% repectively, p<0·001). Interpretation: The benefit of tocilizumab in severe SARS-Cov-2 pneumonia is only expected when it is administrated before the need of high oxygen support. Funding: None.
Open AccessCompassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late
Summary: Introduction: Tocilizumab is an interleukin 6 receptor antagonist which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), aiming to ameliorate the cytokine release syndrome (CRS) -induced acute respiratory distress syndrome (ARDS). However, there is no data about the best moment for its administration along the course of the disease. Methods: We provided tocilizumab on a compassionate-use basis to patients with SSP hospitalized (excluding intensive care and intubated cases) who required oxygen support to have a saturation >93%. Primary endpoint was intubation or death after 24 hours of its administration. Patients received at least one dose of 400 mg intravenous tocilizumab during March 8-2020, through April 20-2020. Findings: A total of 207 patients were studied and 186 analysed. The mean age was 65 years and 68% were male. A co-existing condition was present in 68 % of cases. At baseline, 114 (61%) required oxygen support with FiO2 >0.5 % and 72 (39%) ≤0.5%. Early administration of tocilizumab, when the need of oxygen support was still below FiO2 ≤0.5%, was significantly more effective than given it in advanced stages (FiO2 >0.5 %), achieving lower rates of intubation or death (13% vs 37% repectively, p<0·001). Interpretation: The benefit of tocilizumab in severe SARS-Cov-2 pneumonia is only expected when it is administrated before the need of high oxygen support. Funding: None.